Relmada Therapeutics (RLMD) Stock Insights
RLMD$3.44+0.09 +2.69%
$366.94M
Market Cap
-3.55
P/E
—
Forward P/E
68
Score
Relmada Therapeutics (RLMD) Stock Insights
RLMD price $3.44 +0.09 +2.69%
- Ticker
- RLMD
- Price
- $3.44
- Change
- +0.09 +2.69%
- Market cap ?
- $366.94M
- P/E ?
- -3.55
- Dividend yield ?
- 0.00%
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 68
- Value
- 57
- Quality
- 47
- Growth
- 100
Stocklytics score rationale: value 57, quality 47, growth 100.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready…
Insights · Dividends · Forecast · Financials · Learn